Employees: 1,465
Size Hefei Lifeon Pharmaceutical (003020.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $486M, the 3767th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥14.27 on 18 Nov 2026.
Performance Over six months the shares fell 21.2%, against -13.3% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue fell 0.6% over the last twelve months (peer median +11.2%); the operating margin is 10.0% (peer median 8.8%).
Valuation It trades at 18.2× forward earnings against a peer median of 21.3× (3rd cheapest of 6).
Capital Return on invested capital runs 4.4 points above its cost of capital (5.4% WACC).
Next results Next results expected around 20 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.46B | CN¥1.54B | CN¥1.50B | CN¥1.88B | CN¥2.56B |
| Revenue growth | — | +2% | -20% | -27% | — |
| Gross profit | CN¥1.00B | CN¥955M | CN¥1.00B | CN¥944M | CN¥932M |
| EBITDA | n/a | CN¥228M | CN¥238M | CN¥254M | CN¥233M |
| Net income | CN¥153M | CN¥165M | CN¥161M | CN¥227M | CN¥209M |
| Free cash flow | -CN¥439M | CN¥119M | CN¥48.9M | CN¥132M | -CN¥8.40M |
| Capital expenditure | CN¥105M | CN¥118M | CN¥154M | CN¥198M | CN¥246M |
| Total debt | CN¥132M | CN¥114M | CN¥128M | CN¥109M | CN¥254M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 003020.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.6% | -3.9% | 7th lowest of 21 |
| 6-month return | -21.2% | -13.3% | 7th lowest of 21 |
| Distance from 52-week high | -47.2% | -35.5% | 7th lowest of 21 |
| Revenue growth (TTM) | -0.6% | +11.2% | 8th lowest of 21 |
| Operating margin | 10.0% | 8.8% | 11th highest of 21 |
| Forward P/E | 18.2× | 21.3× | 3rd cheapest of 6 |
| ROIC minus cost of capital | +4.4 pp | -3.0 pp | 6th highest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 18.2× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | n/a | 3.3% | -1.1% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | n/a | 8.9% | +9.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 7.3× | -17.2% | +6.3% |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | n/a | n/a | n/a |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | n/a | 5.9% | -4.1% |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | n/a | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | n/a | -4.7% | +105.3% |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 21.3× | 22.1% | +3.5% |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | n/a | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 4.1× | n/a | n/a |
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | n/a | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | n/a | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 42.2× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | n/a | 16.7% | +4.4% |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | n/a | n/a | n/a |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | n/a | n/a | n/a |
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | n/a | -3.8% | +0.7% |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | n/a | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | n/a | -5.4% | +7.6% |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 24.9× | 24.8% | +126.7% |